NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours

(2012) P A Zucali et al.   BRITISH JOURNAL OF CANCER

Targeting TNF-  to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

(2012) A. Calcinotto et al.   JOURNAL OF IMMUNOLOGY

Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells

(2012) Melissa Taylor et al.   Cancer Discovery

Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice

(2011) S. Gingis-Velitski et al.   CANCER RESEARCH

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

(2011) V. Gregorc et al.   CLINICAL CANCER RESEARCH

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

(2011) Abigail F. Welford et al.   JOURNAL OF CLINICAL INVESTIGATION

Macrophages limit chemotherapy

(2011) Michele De Palma et al.   NATURE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)

(2010) H. W.M. van Laarhoven et al.   CLINICAL CANCER RESEARCH

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

(2010) Armando Santoro et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

(2010) Vanesa Gregorc et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

(2009) V Gregorc et al.   BRITISH JOURNAL OF CANCER

Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents

(2009) Y. Shaked et al.   CANCER RESEARCH

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

(2009) Vanesa Gregorc et al.   EUROPEAN JOURNAL OF CANCER

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

(2009) L. G. Daenen et al.   MOLECULAR CANCER THERAPEUTICS

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

(2008) Rose Du et al.   CANCER CELL

Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

(2008) Yuval Shaked et al.   CANCER CELL

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis

(2008) D. Gao et al.   SCIENCE